Vir Biotechnology, Inc. (VIR)
After hours:
| Previous close | 9.49 |
| Open | 9.41 |
| Bid | 9.20 x 800 |
| Ask | 9.90 x 900 |
| Day's range | 9.12 - 9.71 |
| 52-week range | 7.72 - 31.55 |
| Volume | |
| Avg. volume | 1,469,850 |
| Market cap | 1.304B |
| Beta (5Y monthly) | 0.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.50 |
| Earnings date | 21 Feb 2024 - 26 Feb 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 29.75 |
Business WireVir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
SAN FRANCISCO, November 13, 2023--Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Business WireVir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
SAN FRANCISCO, November 10, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 and VIR-2218 could have for chronic hepatitis B (CHB) and chronic hepatitis delta (CHD) patients at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®, taking place in Boston, MA, from November 10-14, 2023. These include one late-breaking poster presentation and o
Business WireVir Biotechnology Ranked the Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500™
SAN FRANCISCO, November 08, 2023--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first for the second year in a row on the 2023 Deloitte Technology Fast 500™, a list of the fastest-growing technology, media, telecommunications, life sciences, fintech and energy tech companies in North America. This is the first time in the 29-year history of the Deloitte Technology Fast 500 program that a company has topped the list for two consecutive years.
